January 6, 2010
VBL Therapeutics to Present at 28th Annual J.P. Morgan Healthcare Conference

FOR IMMEDIATE RELEASE

 

Media Contact:

Caton Lovett, Pure Communications

910-232-7166

 

 

VBL Therapeutics to Present at 28th Annual J.P. Morgan Healthcare Conference

 

Tel Aviv, Israel, January 6, 2010 – VBL Therapeutics today announced that Dror Harats, M.D., chief executive officer, is scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2010 at 9:00 a.m. PST at the Westin St. Francis Hotel in San Francisco.

 

Dr. Harats is expected to discuss the company’s business strategy, and preclinical and clinical progress with VBL’s innovative portfolio of first-in-class treatments for immuno-inflammatory diseases and cancer – including the recent initiation of a Phase 2 clinical trial of VB-201 in patients with psoriasis. Dr. Harats will also outline the company’s goals to advance the clinical development of VB-201 in psoriasis and rheumatoid arthritis, as well as VB-111 in certain cancers in 2010.

 

About VBL Therapeutics

VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents and VB-201 is the lead candidate from this program, which has entered Phase 2 clinical development in patients with psoriasis. In addition, VBL has a proprietary Vascular Targeting System (VTS™) technology platform that has yielded VB-111, the first dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which is expected to enter Phase 2 clinical trials in 2010. The company was founded in 2000 and is based in Tel Aviv, Israel. VBL has 55 granted patents and more than 115 patents pending. For more information on the company, please visit www.vblrx.com.

 

Download a copy of the J.P. Morgan Healthcare Conference Presentation.